<DOC>
	<DOCNO>NCT02549586</DOCNO>
	<brief_summary>This open-label , proof-of-principle two center cohort study evaluate ability autologous hematopoietic stem cell transplantation induce tolerance recipient decease live donor liver transplant ( ASCOTT ) . A maximum 10 participant enter minimum 3 month post liver transplant . The participant undergo autologous hematopoietic stem cell transplant ( HSCT ) `` re-educate '' immune system accept graft without need long term immunosuppression ( tolerance ) .</brief_summary>
	<brief_title>Autologous Hematopoietic Stem Cell Transplantation Allogeneic Organ Transplant Tolerance</brief_title>
	<detailed_description>Although short-term result liver transplantation excellent , need immunosuppression limit quality life long-term survival . Investigators plan examine utility safety autologous hematopoietic stem cell transplantation ( HSCT ) allow withdrawal immunosuppression 10 liver transplant recipient high risk develop recurrent liver damage repeat bout rejection , recurrent disease high likelihood develop serious medical complication complication immune suppression . Hematopoietic stem cell mobilize , purify cryopreserved . Following chemotherapy Anti-thymocyte Globulin ( ATG ) based-regimen immune ablation , purified stem cell thaw infuse back participant ( autologous hematopoietic stem cell transplant - HSCT ) . Participants convert everolimus , mammalian target rapamycin inhibitor ( mTORi ) , continue 6 month withdraw base histologic evidence graft acceptance . Participants follow closely total 24 month biochemical histologic evidence tolerance rejection . Re-vaccination common viral bacterial antigen undertaken require use standard protocol recipient hematopoietic stem cell transplant ( HSCT ) .</detailed_description>
	<criteria>1 . Participants must 18 year age old . 2 . Participants must minimum 6 month posttransplant ; 3 . Participants recipients hepatic allograft alcohol induce liver disease ; genetic form liver disease hemochromatosis Wilson 's disease ; autoimmune liver disease include sclerosing cholangitis , autoimmune hepatitis , and/or primary biliary cirrhosis . 4 . Participants complication transplantation might ameliorate HSCT and/or withdrawal immunosuppression : evidence recurrent autoimmune disease graft ; repeat episode ( minimum 2 ) acute cellular rejection ; and/ development adverse event relate immune suppression well manage conventional method include drug dose reduction substitution medication . Examples include progression renal dysfunction , repeat infection , neurologic complication , cardiovascular complication , posttransplant lymphoproliferative disease ( PTLD ) remission least 12 month . These complication must deem serious enough warrant inclusion study investigator . 1 . Participants &lt; 18 yr. 2 . Participants cardiac , renal , pulmonary , hepatic , organ impairment would limit ability receive dose intensive chemotherapy ; 3 . Participants active chronic infection . Participants previous reactivation EpsteinBarr virus , cytomegalovirus , BK , human herpesvirus 6 varicellazoster virus would consider eligible virus return latent state ; 4 . Participants seropositive HIV1 , HIV2 , Hepatitis B Surface Antigen , Hepatitis C ; 5 . Participants previous history malignancy squamous basal cell carcinoma skin , posttransplant lymphoproliferative disease ( PTLD ) ; 6 . Participants whose life expectancy severely limit another comorbid illness ; 7 . Participants evidence myelodysplasia , nonautoimmune cytopenia , inherited immunodeficiency state ; 8 . Pregnancy Participants unwilling practice two active form contraception time chemotherapy administration . Participants must willing commit become pregnant enrollment study 2 year follow HSCT . 9 . Participants unable comply medical treatment specify protocol ; 10 . Participants unable give write informed consent accordance research ethic board guideline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>solid organ transplant</keyword>
	<keyword>immune tolerance</keyword>
	<keyword>autologous stem cell transplant</keyword>
	<keyword>blood marrow transplant</keyword>
	<keyword>autoimmune disease</keyword>
</DOC>